{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:46:10Z","timestamp":1782459970442,"version":"3.54.5"},"reference-count":63,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-006"],"award-info":[{"award-number":["2023-I2M-2-006"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-TS-016"],"award-info":[{"award-number":["2024-I2M-TS-016"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2025-I2M-KJ-019"],"award-info":[{"award-number":["2025-I2M-KJ-019"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-05"],"award-info":[{"award-number":["2021-I2M-1-05"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82574403"],"award-info":[{"award-number":["82574403"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404723"],"award-info":[{"award-number":["82404723"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fundamental Research Funds for the Central Universities, Peking Union Medical College","award":["3332025163"],"award-info":[{"award-number":["3332025163"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Osteoporosis is a systemic skeletal disease that severely impairs the health of the elderly population. The interaction between the receptor activator of the NF-\u03baB ligand (RANKL) and its receptor RANK is critical for osteoclast differentiation and function. Therefore, targeting the RANKL\/RANK interaction represents a promising strategy for osteoporosis. In this study, we employed a newly established yeast two-hybrid system based on RANKL\/RANK interaction and identified IMB-R38, a novel benzamide compound that dose-dependently blocked RANKL\/RANK interaction by inhibiting the growth of AH109 cells harboring pAD-RANKL\/pBD-RANK plasmids in quadruple-dropout medium. IMB-R38 significantly suppressed osteoclast differentiation, disrupted F-actin ring formation, and downregulated the expression of osteoclast-specific genes, including NFATc1 and MMP9 in RANKL-induced RAW264.7 macrophages. IMB-R38 also promoted osteoblast differentiation by upregulating the expression of osteogenic genes. Importantly, in a dexamethasone (DXM)-induced osteoporotic zebrafish model, IMB-R38 significantly increased bone mineralization, with anti-osteoporosis efficacy superior to that of alendronate sodium (Alen). RT-qPCR assays showed that IMB-R38 significantly upregulated the mRNA expression of osteogenesis genes (Bmp2, Runx2a, Runx2b, Sp7, Alp, and Oc) while markedly downregulating that of the osteoclastogenesis genes (Mmp9, Mmp13, and Mmp2) compared with the DXM group. Mechanistically, an SPR assay confirmed that IMB-R38 directly binds with RANK but not RANKL to disrupt RANKL\/RANK interaction. Furthermore, Asp168 of RANK was identified as a key amino acid that mediates both RANKL interaction and IMB-R38 binding. The inhibition of RANKL\/RANK by IMB-R38 suppressed JNK phosphorylation and, consequently, osteoclast differentiation and function. Collectively, our findings identify IMB-R38 as a novel RANKL\/RANK inhibitor with therapeutic potential for osteoporosis through its regulation of bone metabolism.<\/jats:p>","DOI":"10.3390\/ijms262412151","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:53:46Z","timestamp":1765986826000},"page":"12151","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Novel RANKL\/RANK Inhibitor IMB-R38 Inhibits Osteoporosis Through Regulating Bone Metabolism"],"prefix":"10.3390","volume":"26","author":[{"given":"Yuyan","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Wei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Sheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowan","family":"Han","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunwang","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Lei","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilian","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lun","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Si","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Bioactive Substance and Function of Natural Medicines, NHC Key Laboratory of Microbial Drugs, National Center for New Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tiantan Xili 1#, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal Osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1186\/s12967-023-04563-z","article-title":"Romosozumab in osteoporosis: Yesterday, today and tomorrow","volume":"21","author":"Wu","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.mayocp.2022.03.011","article-title":"Skeletal Aging","volume":"97","author":"Sfeir","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00198-021-05877-8","article-title":"Incremental costs of fragility fractures: A population-based matched -cohort study from Ontario, Canada","volume":"32","author":"Tarride","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Amin, U., McPartland, A., O\u2019Sullivan, M., and Silke, C. (2023). An overview of the management of osteoporosis in the aging female population. Women\u2019s Health, 19.","DOI":"10.1177\/17455057231176655"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","article-title":"Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: A systematic review and meta-analysis","volume":"33","author":"Xiao","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/jbmr.4544","article-title":"Harmonization of Osteoporosis Guidelines: Paving the Way for Disrupting the Status Quo in Osteoporosis Management in the Asia Pacific","volume":"37","author":"Chandran","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Song, S., Guo, Y., Yang, Y., and Fu, D. (2022). Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol. Ther., 237.","DOI":"10.1016\/j.pharmthera.2022.108168"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Domotor, Z.R., Vorhendi, N., Hanak, L., Hegyi, P., Kiss, S., Csiki, E., Szako, L., Parniczky, A., and Eross, B. (2020). Oral Treatment with Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.573976"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2024.08.008","article-title":"Postmenopausal Osteoporosis: A Review of Latest Guidelines","volume":"53","author":"Subarajan","year":"2024","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1093\/ejendo\/lvae076","article-title":"Romosozumab versus parathyroid hormone receptor agonists: Which osteoanabolic to choose and when?","volume":"191","author":"Anastasilakis","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1146\/annurev-pathol-011110-130203","article-title":"Disorders of bone remodeling","volume":"6","author":"Feng","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/GRF.0000000000000572","article-title":"Bone Health and Osteoporosis Prevention and Treatment","volume":"63","author":"Munoz","year":"2020","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tobeiha, M., Moghadasian, M.H., Amin, N., and Jafarnejad, S. (2020). RANKL\/RANK\/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Biomed. Res. Int., 2020.","DOI":"10.1155\/2020\/6910312"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liang, J., Liu, P., Wang, Q., Liu, L., and Zhao, H. (2022). The RANK\/RANKL\/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1063815"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-007-0024-y","article-title":"The RANKL\/RANK\/OPG pathway","volume":"5","author":"Boyce","year":"2007","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Monti, F., Perazza, F., Leoni, L., Stefanini, B., Ferri, S., Tovoli, F., Zavatta, G., Piscaglia, F., Petroni, M.L., and Ravaioli, F. (2024). RANK-RANKL-OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25179193"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41413-024-00362-4","article-title":"Mapping RANKL- and OPG-expressing cells in bone tissue: The bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect","volume":"12","author":"Andreasen","year":"2024","journal-title":"Bone Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14728222.12.4.505","article-title":"The yeast two-hybrid system and its role in drug discovery","volume":"12","author":"Lentze","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhou, S., Huang, G., and Chen, G. (2020). Synthesis and biological activities of drugs for the treatment of osteoporosis. Eur. J. Med. Chem., 197.","DOI":"10.1016\/j.ejmech.2020.112313"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41597-021-01012-8","article-title":"Murine femur micro-computed tomography and biomechanical datasets for an ovariectomy-induced osteoporosis model","volume":"8","author":"Stephens","year":"2021","journal-title":"Sci. Data"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jiang, T., Xia, T., Qiao, F., Wang, N., Jiang, Y., and Xin, H. (2023). Role and Regulation of Transcription Factors in Osteoclastogenesis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216175"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhu, L., Tang, Y., Li, X.Y., Keller, E.T., Yang, J., Cho, J.S., Feinberg, T.Y., and Weiss, S.J. (2020). Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Sci. Transl. Med., 12.","DOI":"10.1126\/scitranslmed.aaw6143"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Akiyama, T., Raftery, L.A., and Wharton, K.A. (2024). Bone morphogenetic protein signaling: The pathway and its regulation. Genetics, 226.","DOI":"10.1093\/genetics\/iyad200"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Halloran, D., Durbano, H.W., and Nohe, A. (2020). Bone Morphogenetic Protein-2 in Development and Bone Homeostasis. J. Dev. Biol., 8.","DOI":"10.3390\/jdb8030019"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41421-024-00689-6","article-title":"Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","article-title":"Wnt\/beta-catenin signaling components and mechanisms in bone formation, homeostasis, and disease","volume":"12","author":"Hu","year":"2024","journal-title":"Bone Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Bordukalo-Niksic, T., Kufner, V., and Vukicevic, S. (2022). The Role of BMPs in the Regulation of Osteoclasts Resorption and Bone Remodeling: From Experimental Models to Clinical Applications. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.869422"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Komori, T. (2022). Whole Aspect of Runx2 Functions in Skeletal Development. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105776"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Hadavi, D., Dijkgraaf, I., and Honing, M. (2024). Coupling of surface plasmon resonance and mass spectrometry for molecular interaction studies in drug discovery. Drug Discov. Today, 29.","DOI":"10.1016\/j.drudis.2024.104027"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"ref_34","first-page":"299","article-title":"Targeting the RANK\/RANKL\/OPG signaling pathway: A novel approach in the management of osteoporosis","volume":"8","author":"Hamdy","year":"2007","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nrendo.2015.71","article-title":"Short-term and long-term effects of osteoporosis therapies","volume":"11","author":"Reid","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL Pathway in Multiple Myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for Infections During Treatment with Denosumab for Osteoporosis: A Systematic Review and Meta-analysis","volume":"105","author":"Rosenberg","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00198-021-06268-9","article-title":"Cost-effectiveness analyses of denosumab for osteoporosis: A systematic review","volume":"33","author":"Wan","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Nakai, Y., Okamoto, K., Terashima, A., Ehata, S., Nishida, J., Imamura, T., Ono, T., and Takayanagi, H. (2019). Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis. Bone Res., 7.","DOI":"10.1038\/s41413-018-0036-5"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Xu, H., Chen, F., Liu, T., Xu, J., Li, J., Jiang, L., Wang, X., and Sheng, J. (2020). Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways. Chem. Biol. Interact., 331.","DOI":"10.1016\/j.cbi.2020.109235"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Xu, H., Jia, Y., Li, J., Huang, X., Jiang, L., Xiang, T., Xie, Y., Yang, X., Liu, T., and Xiang, Z. (2022). Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-kappaB signaling pathways. Biomed. Pharmacother., 149.","DOI":"10.1016\/j.biopha.2022.112902"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Chen, P., and Lin, J. (2025). Bushen Jiangu decoction alleviates osteoporosis by inhibiting MMP2 expression and activation of the MAPK pathway in vitro. Tissue Cell, 96.","DOI":"10.1016\/j.tice.2025.103025"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ullah, A., Chen, Y., Singla, R.K., Cao, D., and Shen, B. (2024). Exploring cytokines dynamics: Uncovering therapeutic concepts for metabolic disorders in postmenopausal women- diabetes, metabolic bone diseases, and non-alcohol fatty liver disease. Ageing Res. Rev., 101.","DOI":"10.1016\/j.arr.2024.102505"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"10257","DOI":"10.1038\/s41598-022-14470-w","article-title":"Mmp13 deletion in mesenchymal cells increases bone mass and may attenuate the cortical bone loss caused by estrogen deficiency","volume":"12","author":"Ponte","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1089\/scd.2021.0146","article-title":"SP600125 Restored TNF-alpha-Induced Impaired Chondrogenesis in Bone Mesenchymal Stem Cells and Its Antiosteoarthritis Effect in Mice","volume":"30","author":"Ding","year":"2021","journal-title":"Stem Cells Dev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/BOR.0000000000000845","article-title":"Blood and urine biomarkers in osteoarthritis\u2014An update on cartilage associated type II collagen and aggrecan markers","volume":"34","author":"Mobasheri","year":"2022","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"C1061","DOI":"10.1152\/ajpcell.00086.2022","article-title":"Emerging proteoglycans and proteoglycan-targeted therapies in rheumatoid arthritis","volume":"322","author":"Hurysz","year":"2022","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Qu, Z., Zhao, S., Zhang, Y., Wang, X., and Yan, L. (2024). Natural Compounds for Bone Remodeling: Targeting osteoblasts and relevant signaling pathways. Biomed. Pharmacother., 180.","DOI":"10.1016\/j.biopha.2024.117490"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cbi.2012.12.016","article-title":"RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-kappaB activation and down regulating inflammatory cytokines","volume":"203","author":"Naidu","year":"2013","journal-title":"Chem. Biol. Interact."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"17412","DOI":"10.1073\/pnas.1110271109","article-title":"Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid system","volume":"109","author":"Lin","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.abb.2009.04.008","article-title":"The affinity of human RANK binding to its ligand RANKL","volume":"487","author":"Zhang","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ijbiomac.2022.03.088","article-title":"Strontium based Astragalus polysaccharides promote osteoblasts differentiation and mineralization","volume":"205","author":"Peng","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Li, C., Tian, L., Wang, Y., Luo, H., Zeng, J., Su, P., Chen, S., Liao, Z., Guo, W., and He, X. (2023). M13, an anthraquinone compound isolated from Morinda officinalis promotes the osteogenic differentiation of MSCs by targeting Wnt\/beta-catenin signaling. Phytomedicine, 108.","DOI":"10.1016\/j.phymed.2022.154542"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Li, Y., Liu, C., Han, X., Sheng, R., Bao, L., Lei, L., Wu, Y., Li, Q., Zhang, Y., and Zhang, J. (2024). The novel small molecule E0924G dually regulates bone formation and bone resorption through activating the PPARdelta signaling pathway to prevent bone loss in ovariectomized rats and senile mice. Bioorganic Chem., 147.","DOI":"10.1016\/j.bioorg.2024.107364"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yu, M., Zhang, J., Fu, J., Li, S., and Cui, X. (2025). Guizhi Fuling decoction protects against bone destruction via suppressing exosomal ERK1 in multiple myeloma. Phytomedicine, 140.","DOI":"10.1016\/j.phymed.2025.156627"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Tao, Z.S., Hu, X.F., Wu, X.J., Wang, Z.Y., Yang, M., and Shen, C.L. (2024). Ganoderic Acid A prevents bone loss in lipopolysaccharide-treated male rats by reducing oxidative stress and inflammatory. Chem. Biol. Interact., 401.","DOI":"10.1016\/j.cbi.2024.111164"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Jin, W., Chen, F., Fang, Q., Mao, G., and Bao, Y. (2023). Oligosaccharides from Sargassum thunbergii inhibit osteoclast differentiation via regulation of IRF-8 signaling. Exp. Gerontol., 172.","DOI":"10.1016\/j.exger.2022.112057"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Li, S., Li, Y., Yu, T., Wei, X., Zhang, Y., Chen, B., Si, S., Xu, Y., and Gan, M. (2025). Discovery of potent antiosteoporotic cyclic depsipeptides with an unusual nitrile hydroxy acid from Microascus croci. Bioorganic Chem., 155.","DOI":"10.1016\/j.bioorg.2025.108133"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Jafari","year":"2013","journal-title":"Science"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12151\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:13:11Z","timestamp":1766121191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":63,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412151"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412151","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}